Cargando…
Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center
Relapsed/refractory acute myeloid leukemia (AML) is a devastating disease with a poor prognosis and represents a major unmet medical need. We report on a real-world academic center experience of treating 25 patients with relapsed/refractory AML using venetoclax in combination with decitabine or azac...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991747/ https://www.ncbi.nlm.nih.gov/pubmed/33777810 http://dx.doi.org/10.3389/fonc.2021.649209 |
_version_ | 1783669232136880128 |
---|---|
author | Tenold, Matthew E. Moskoff, Benjamin N. Benjamin, David J. Hoeg, Rasmus T. Rosenberg, Aaron S. Abedi, Mehrdad Tuscano, Joseph M. Jonas, Brian A. |
author_facet | Tenold, Matthew E. Moskoff, Benjamin N. Benjamin, David J. Hoeg, Rasmus T. Rosenberg, Aaron S. Abedi, Mehrdad Tuscano, Joseph M. Jonas, Brian A. |
author_sort | Tenold, Matthew E. |
collection | PubMed |
description | Relapsed/refractory acute myeloid leukemia (AML) is a devastating disease with a poor prognosis and represents a major unmet medical need. We report on a real-world academic center experience of treating 25 patients with relapsed/refractory AML using venetoclax in combination with decitabine or azacitidine, which is not otherwise widely evaluated in the current literature. Our patients come from a large, socioeconomically and geographically diverse area including the majority of Northern California. Most had ELN Adverse Risk (52%) or Intermediate Risk (44%) AML, and most had an ECOG Performance Status of 1 (64%). Over half (52%) had prior hypomethylating agent exposure, and 40% had Secondary AML. We observed an overall response rate of 52%, with eight patients (32%) achieving composite complete remission. Median overall survival was 5.5 months, and for patients achieving composite complete remission this was 21.6 months. One-year estimated overall survival was 38%. Three patients were able to proceed directly to stem cell transplant for consolidation, and all three were alive at last follow-up, ranging 13.8–24.0 months. We found venetoclax in combination with hypomethylating agents to be well tolerated and potentially efficacious in securing long-term remissions for patients with relapsed/refractory AML. |
format | Online Article Text |
id | pubmed-7991747 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79917472021-03-26 Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center Tenold, Matthew E. Moskoff, Benjamin N. Benjamin, David J. Hoeg, Rasmus T. Rosenberg, Aaron S. Abedi, Mehrdad Tuscano, Joseph M. Jonas, Brian A. Front Oncol Oncology Relapsed/refractory acute myeloid leukemia (AML) is a devastating disease with a poor prognosis and represents a major unmet medical need. We report on a real-world academic center experience of treating 25 patients with relapsed/refractory AML using venetoclax in combination with decitabine or azacitidine, which is not otherwise widely evaluated in the current literature. Our patients come from a large, socioeconomically and geographically diverse area including the majority of Northern California. Most had ELN Adverse Risk (52%) or Intermediate Risk (44%) AML, and most had an ECOG Performance Status of 1 (64%). Over half (52%) had prior hypomethylating agent exposure, and 40% had Secondary AML. We observed an overall response rate of 52%, with eight patients (32%) achieving composite complete remission. Median overall survival was 5.5 months, and for patients achieving composite complete remission this was 21.6 months. One-year estimated overall survival was 38%. Three patients were able to proceed directly to stem cell transplant for consolidation, and all three were alive at last follow-up, ranging 13.8–24.0 months. We found venetoclax in combination with hypomethylating agents to be well tolerated and potentially efficacious in securing long-term remissions for patients with relapsed/refractory AML. Frontiers Media S.A. 2021-03-11 /pmc/articles/PMC7991747/ /pubmed/33777810 http://dx.doi.org/10.3389/fonc.2021.649209 Text en Copyright © 2021 Tenold, Moskoff, Benjamin, Hoeg, Rosenberg, Abedi, Tuscano and Jonas http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Tenold, Matthew E. Moskoff, Benjamin N. Benjamin, David J. Hoeg, Rasmus T. Rosenberg, Aaron S. Abedi, Mehrdad Tuscano, Joseph M. Jonas, Brian A. Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center |
title | Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center |
title_full | Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center |
title_fullStr | Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center |
title_full_unstemmed | Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center |
title_short | Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center |
title_sort | outcomes of adults with relapsed/refractory acute myeloid leukemia treated with venetoclax plus hypomethylating agents at a comprehensive cancer center |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991747/ https://www.ncbi.nlm.nih.gov/pubmed/33777810 http://dx.doi.org/10.3389/fonc.2021.649209 |
work_keys_str_mv | AT tenoldmatthewe outcomesofadultswithrelapsedrefractoryacutemyeloidleukemiatreatedwithvenetoclaxplushypomethylatingagentsatacomprehensivecancercenter AT moskoffbenjaminn outcomesofadultswithrelapsedrefractoryacutemyeloidleukemiatreatedwithvenetoclaxplushypomethylatingagentsatacomprehensivecancercenter AT benjamindavidj outcomesofadultswithrelapsedrefractoryacutemyeloidleukemiatreatedwithvenetoclaxplushypomethylatingagentsatacomprehensivecancercenter AT hoegrasmust outcomesofadultswithrelapsedrefractoryacutemyeloidleukemiatreatedwithvenetoclaxplushypomethylatingagentsatacomprehensivecancercenter AT rosenbergaarons outcomesofadultswithrelapsedrefractoryacutemyeloidleukemiatreatedwithvenetoclaxplushypomethylatingagentsatacomprehensivecancercenter AT abedimehrdad outcomesofadultswithrelapsedrefractoryacutemyeloidleukemiatreatedwithvenetoclaxplushypomethylatingagentsatacomprehensivecancercenter AT tuscanojosephm outcomesofadultswithrelapsedrefractoryacutemyeloidleukemiatreatedwithvenetoclaxplushypomethylatingagentsatacomprehensivecancercenter AT jonasbriana outcomesofadultswithrelapsedrefractoryacutemyeloidleukemiatreatedwithvenetoclaxplushypomethylatingagentsatacomprehensivecancercenter |